CME/CE Podcast: Managing Residual Risk in Chronic Kidney Disease: The Role of Non-Steroidal MRAs

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/the-role-of-non-steroidal-mras-in-chronic-kidney-disease-8866

Featuring faculty Robert D. Toto, MD, moderated by Gregg Sherman, MD.

Summary
Chronic kidney disease (CKD) is estimated to affect 20%–40% of patients with diabetes mellitus. In renal disease, increased production of aldosterone and other mediators leads to overactivation of the mineralocorticoid receptor (MR). In turn, overactivation of the MR can drive progression of renal disease. Through these mechanisms, increased aldosterone production and MR overactivation contribute to adverse renal, cardiac, and vascular effects. Traditional steroidal MR antagonists (MRAs) are beneficial but are associated with hyperkalemia. However, a newer nonsteroidal MRA is available that targets MR overactivation without the risk of hyperkalemia.

In this second of two podcast episodes, Dr. Robert Toto and Dr. Gregg Sherman discuss identifying appropriate candidates for nonsteroidal MRAs, as well as incorporating these therapies into the management of CKD of T2D.

This podcast was recorded and is being used with permission of the presenters.

Learning Objective
Upon completion of this activity, learners should be able to:

• Identify patients with CKD and T2D who are appropriate candidates for non-steroidal MRAs to manage residual risk

This activity is accredited for CME/CE Credit.
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

Summary of Individual Disclosures
Robert Toto has disclosed the following financial relationships:

• Consultant: Amgen (Anemia in CKD), AstraZeneca (CKD), Akebia (Anemia in CKD), Bayer (CKD), Boehringer Ingelheim (CKD), Medscape (CKD anemia and hyperkalemia), Novartis (CKD), Novo Nordisk (Diabetic Kidney Disease), Otsuka (Anemia in CKD), Vifor (CKD), CinCor (CKD)
• Advisor – Unicycive (hyperphosphatemia in CKD)

Angela Golden has disclosed the following financial relationships:

• Consultant: SetPoint (Obesity), WW (Obesity)
• Advisor: Currax (Obesity), Genesis (Obesity), Lilly (Obesity), Novo Nordisk (Obesity), (Obesity), Acela (Hypothyroidism)
• Speaker: Currax, Novo Nordisk (Obesity)
• Receipt of Royalty: Amazon (fiction books), Springer (obesity book)

Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure of Commercial Support
This activity has been supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.